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Abstract: Vancomycin is the drug of choice for methicillin-resistant Staphylococcus aureus keratitis and
other ocular infections. Vancomycin ophthalmic drops are not commercially available and require
compounding. The present study was designed to investigate the stability of vancomycin ophthalmic
drops in normal saline, phosphate-buffered saline (PBS), and balanced salt solution (BSS) while
stored at room temperature or under refrigeration. Vancomycin ophthalmic drops (50 mg/mL) were
aseptically prepared from commercially available intravenous powder using PBS, BSS, and saline.
Solutions were stored at room temperature and in a refrigerator for 28 days. The vancomycin stability
was tested by a microbiology assay and high-performance liquid chromatography HPLC analysis
immediately after formulation and at days 7, 14, and 28 after storage at room temperature or under
refrigeration. The pH, turbidity was also tested. Vancomycin formulations in PBS, BSS and normal
saline had initial pH of 5; 5.5; 3 respectively. The formulation in PBS developed turbidity and a slight
decrease in pH upon storage. Microbiological assay did not show any change in zone of inhibition
with any of the formulation upon storage either at room temperature or under refrigeration. HPLC
analysis did not detect any decrease in vancomycin concentration or the accumulation of degraded
products in any of the formulations upon storage either at room temperature or under refrigeration.
Vancomycin ophthalmic drops prepared using PBS, BSS, and normal saline were stable up to the
tested time point of 28 days, irrespective of their storage temperature.
Keywords: MRSA; keratitis; vancomycin; compounding; stability
1. Introduction
Keratitis is an infection of the cornea caused by bacteria, fungi, herpes virus, or acan-
thamoeba. It is a sight-threatening medical emergency requiring prompt and effective
intervention. Staphylococcus aureus is the second most common pathogen causing bacte-
rial keratitis, although the exact incidence of infection varies by geographic location [1,2].
Methicillin-resistant S. aureus (MRSA) are strains of S. aureus resistant to the all antibi-
otics within the β-lactam class, except ceftaroline [3–5]. The acquisition of the mecA or
mecC genes, which lead to alternative penicillin-binding proteins, account for the most
common mechanism of resistance that results in the methicillin-resistant phenotype [6–9].
Although historically considered a hospital-acquired infection, MRSA clones are increas-
ingly being encountered among community infections [10–12]. MRSA is known to cause a
variety of ocular infections, including keratitis [13–15]. The incidence of MRSA ocular in-
fections in the United States has been rising in recent years, with multiple studies reporting
that MRSA accounts for roughly 30–40% of all S. aureus cases of keratitis [16–18].
The American Academy of Ophthalmology recommends 1.2%, 2.5%, or 5% van-
comycin ophthalmic drops for keratitis caused by MRSA [19]. Alternatively, fluoro-
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quinolone ophthalmic drops, which are commercially available, have been anecdotally used
for MRSA keratitis, but ocular MRSA infections respond poorly, and the incidence of fluoro-
quinolone resistance remains a serious concern [20,21]. On the contrary, MRSA-associated
keratitis isolates are largely responsive to vancomycin, which is the gold standard MRSA
treatment for a wide range of different infection types, and resistance is rare [21,22].
A recent study has reported that 5% vancomycin ophthalmic drops have a higher efficacy
in treating MRSA keratitis compared to lower concentrations [22]. However, vancomycin
ophthalmic drops are not available commercially and require preparation by a licensed
compounding pharmacy. The compounding pharmacy is required to be a member of
the Pharmacy Compounding Accreditation Board 152 and designated by the FDA as a
503A and/or 503B facility. The American Academy of Ophthalmology’s preferred prac-
tices pattern guidelines recommend the use of sterile normal saline for compounding
vancomycin and its subsequent storage under refrigeration [19]. However, case reports
and circumstantial evidence show that, besides normal saline, phosphate-buffered saline
(PBS) and balanced salt solution (BSS) have also been used for compounding vancomycin.
The requirement of compounding vancomycin ophthalmic drops leads to an increased
financial cost for the patient, and the drops are typically recommended to be discarded
after seven days despite the possibility of a longer shelf-life. Additionally, some patients
with keratoprosthetics will require the use of ophthalmic vancomycin for longer dura-
tions [23,24]. These clinical needs necessitate the evaluation of the stability of compounded
vancomycin ophthalmic drops. There are no comprehensive studies that evaluate the
stability of compounded vancomycin ophthalmic drops in normal saline, PBS, and BSS
with storage conditions either under refrigeration or at room temperature. Therefore,
the present study was designed to investigate the stability of compounded vancomycin
ophthalmic drops in normal saline, PBS, and BSS while stored at room temperature or
under refrigeration, using the United States Pharmacopeia-recommended microbiological
assay [25] and a high-performance liquid chromatography (HPLC) analysis.
2. Materials and Methods
2.1. Preparation of Vancomycin Ophthalmic Drops
Vancomycin eye drops were prepared aseptically from commercially available lyophilized
powder of vancomycin hydrochloride (Mylan Pharmaceuticals, Morgantown, WV, USA)
intended for intravenous use. A 50-mg/mL solution of vancomycin hydrochloride was
prepared using three different vehicles: 1× phosphate-buffered saline (PBS), balanced salt
solution (BSS), and normal saline. Each solution was then aliquoted into two equal parts
with storage at room temperature and at 4 ◦C in a refrigerator.
The formulations were tested for pH and turbidity immediately after formulation and
then at days 7, 14, and 28 after storage.
2.2. Stability Testing of Vancomycin Ophthalmic Drops
The stability of vancomycin ophthalmic drops prepared in three different vehicles and
stored under two different conditions were tested using a HPLC chemical analysis and
microbiological assay. The assays were performed using freshly prepared solutions imme-
diately after formulation and then at days 7, 14, and 28 after the preparation and storage.
(a) Chemical Analysis of vancomycin using HPLC method
The HPLC method was used to quantify the vancomycin concentrations in the
aliquots of the three ophthalmic formulations stored under two different conditions im-
mediately after formulation and then at days 7, 14, and 28 after preparation and storage.
The HPLC chromatograms were also run to screen for any additional peaks indicative of
degradation products. A freshly prepared solution of vancomycin was used as a standard.
The vancomycin ophthalmic formulation samples were diluted to be analyzed at 1-mg/mL
concentrations. The sample concentration was calculated against five-point (2, 1, 0.5, 0.25,
and 0.125 mg/mL) vancomycin standard curve concentrations. The HPLC analysis was
done on a Hitachi LaChrome Ultra,(Hitachi High-Tech, Dallas, TX, USA) equipped with an
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autosampler and UV/Vis detector, using Vydac 218tp54, 250 × 4.6 mm, 5-um particle size,
and C18 column. Mobile phase A, 0.1% trifluoroacetic acid (TFA) in water, was prepared
by mixing 1 mL of TFA to 1 L of water and sonicating for 10 min. Mobile phase B, 0.1% TFA
in acetonitrile, was prepared by mixing 1 mL of TFA to 1 L of acetonitrile and sonicating
for 10 min. The flow rate was 1.0 mL/min with the following gradient method: hold
at 10% mobile phase B+ 90% mobile phase A for 4 min, 10–35% mobile phase B + 65%
mobile phase A for 7 min, and hold at 10% mobile phase B + 90% mobile phase A for 4 min.
A 20-uL sample injection volume of the samples was used, and detection was performed at
the 280-nm wavelength.
(b) Microbiological Assay
The United States Pharmacopeia method was used for the microbiological assay
of vancomycin [25]. The media containing peptone (6 g/L), yeast extract (3 g/L), beef
extract (1.5 g/L), agar (15 g/L), and distilled water (1 L) was used to prepare agar plates.
Eight-millimeter holes were punched in the inoculated agar plates. Aliquots were obtained
from each of the three ophthalmic formulations stored under two different conditions
immediately after formulation and then at days 7, 14, and 28 after preparation and storage.
These aliquots were diluted to an obtained a 1-µg/50-µL concentration of vancomycin, and
50 µL of each of these ophthalmic formulation samples was added to the punched hole
in the agar plate. A freshly prepared solution of 1-µg/50-µL vancomycin was used as a
standard. The plates were then incubated for 24 h at 37 ◦C, and the zone of inhibition in
mm was noted down. The formulations were prepared twice, and each of the samples was
analyzed in duplicate. The presented data is a replicate of n = 4.
2.3. Statistical Analysis
The data are presented as mean ± standard error of mean. Statistical analysis was
performed using GraphPad Prism software (GraphPad Prism, Version 8, San Diego, CA,
USA). The data were analyzed using one-way ANOVA, followed by Dunnett’s post-hoc
test. A p-value of <0.05 was considered statistically significant.
3. Results
3.1. Appearance and PH of Vancomycin Ophthalmic Formulations
Vancomycin formulated in PBS and stored at room temperature or under refrigeration
remained clear for 14 days after preparation, but subsequently, it developed visible turbidity
under both the storage conditions. The BSS and normal saline formulations stored at room
temperature or under refrigeration remained visibly clear up to the tested time point of
28 days.
Table 1 shows the pH of the vancomycin formulations immediately after preparation
and then at various days after storage at room temperature or under refrigeration.
Table 1. The pH of vancomycin formulations in phosphate-buffered saline (PBS), balanced salt
solution (BSS), and normal saline immediately after formulation and then at days 7, 14, and 28 after
storage at room temperature or under refrigeration. RT: room temperate.
Solvent Day 0 Day 7 Day 14 Day 28
PBS—RT 5.0 ± 0 4.5 ± 0 4.5 ± 0 4.5 ± 0
PBS—4 ◦C 5.0 ± 0 4.5 ± 0 4.5 ± 0 4.5 ± 0
BSS—RT 5.5 ± 0 5.5 ± 0 5.5 ± 0 5.5 ± 0
BSS—4 ◦C 5.5 ± 0 5.5 ± 0 5.5 ± 0 5.5 ± 0
Saline—RT 3.0 ± 0 3.0 ± 0 3.0 ± 0 3.0 ± 0
Saline—4 ◦C 3.0 ± 0 3.0 ± 0 3.0 ± 0 3.0 ± 0
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Vancomycin formulated in PBS, BSS, and normal saline had an initial pH of 5, 5.5, and
3, respectively. The pH of the PBS formulation decreased to 4.5 after seven days in both the
samples stored at room temperature and under refrigeration. After this initial decrease,
no further decrease in pH was noted in this PBS formulation up to the tested time point
of 28 days. On the other hand, the BSS and normal saline formulations did not show any
change in pH with storage either at room temperature or under refrigeration.
3.2. HPLC Quantification of Vancomycin Ophthalmic Formulations
Figure 1 shows the HPLC quantification of the PBS, BSS, and normal saline formula-
tions of vancomycin immediately after preparation and then at various days after storage
at room temperature or under refrigeration. The HPLC analysis did not detect any signifi-
cant decrease in the vancomycin concentration after storage in any of these formulations.
Furthermore, the stability of vancomycin was not affected by the storage temperature,
since no significant difference in the vancomycin concentrations was noted whether the
formulations were stored at room temperature or under refrigeration.
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Figure 1. Quantification of vancomycin (mg/mL) in the phosphate-buffered saline (PBS), balances salt
solution (BSS), and normal saline formulations analyzed by high-performance liquid chromatography
(HPLC) immediately after formulation and then at days 7, 14, and 28 after storage at room temperature
or under refrigeration. The data is presented as mean ± standard error of mean (SEM).
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The HPLC chromatograms showed a vancomycin peak with an average elution time
of 9.5 min in all these formulations when analyzed immediately after preparation.
Subsequently, an identical vancomycin peak with a similar elution time was also
detected in these formulation samples upon analysis. There were no additional peaks in
the HPLC chromatogram of the vancomycin formulations upon storage either at room
temperature or under refrigeration compared to the freshly prepared vancomycin standard,
suggesting that vancomycin did not have any degradation product formations upon storage
in any of the three formulations stored either at room temperature or under refrigeration.
3.3. Microbiology Assay of Vancomycin Ophthalmic Formulations
A change in the bactericidal activity of antibiotics in microbiology assays is a reliable
and activity-based indicator of a loss of potency. Therefore, we next tested the potency of
vancomycin in the ophthalmic formulations using the microbiological assay method rec-
ommended by the United States Pharmacopeia [25]. Figure 2 shows the zone of inhibition
of vancomycin in the formulations prepared using PBS, BSS, and normal saline. The zone
of inhibition assay was performed in these formulations immediately after preparation,
and then at 7 days, 14 days, and 28 days after compounding. No significant decrease in the
zone of inhibition was observed in any of the formulations tested at the various time points
upon storage when compared to the zone of inhibition analyzed in these formulations
immediately upon preparation. Therefore, the microbiological assay data suggest that the
vancomycin formulations did not lose potency upon storage either at room temperature or
under refrigeration.
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4. Discussion
The topical application of vancomycin is the sight-saving treatment for keratitis caused
by vancomycin-susceptible bacteria resistant to other antibiotic classes [20–22,26–28]. Topi-
cal vancomycin has also been used for preventing devastating ocular infections in patients
who receive keratoprosthetics [23,24,29]. The treatment duration for keratitis typically
requires approximately one to two weeks of application, and keratoprosthetics prophylaxis
can last for a much longer duration [20–24,26–29]. There are currently no commercially
available vancomycin ophthalmic formulations, thus necessitating compounding by a
licensed pharmacy. Vancomycin ophthalmic drops need to be compounded under sterile
conditions. These requirements make vancomycin ophthalmic drops expensive. The re-
peated compounding of vancomycin drops for the duration of a treatment further adds
to the cost and the inconvenience of making additional trips to the pharmacy for picking
up the drops, which can adversely affect patient adherence. The results of the present
study demonstrate that compounded vancomycin eye drops are stable up to the tested
time points of 28 days. Based on our data, it is feasible to compound larger quantities of
vancomycin ophthalmic drops and then aliquot them into multiple smaller sterile contain-
ers for dispensing to the patient. This approach will reduce the cost while still maintaining
the sterility if the patient is adequately counseled on opening and using one container at
a time.
The American Academy of Ophthalmology’s preferred practice pattern guidelines
recommend the use of sterile normal saline for compounding vancomycin [19]. However,
a variety of other solvents have also been used. The differences in ionic composition,
pH, and buffering capacity of these solvents can affect the physicochemical stability of
vancomycin. In the present study, we used a microbiological assay, as well as a HPLC-
mediated chemical analysis, to compare the stability of vancomycin in three different
formulations. Microbiological testing is a functional assay providing direct evidence of
bactericidal activity. If an antibiotic has conformational changes, it may cause a decrease in
its potency without causing any detectable changes in the HPLC analysis. On the other
hand, a slight chemical degradation may not affect the antimicrobial activity of an antibiotic
in the microbiology assay, but the accumulation of degradation products could be a concern
for potential toxicity. The HPLC analysis is a sensitive assay to detect any additional peaks
arising from the degrading products. Using these two assays, the results of the present
study demonstrate that the stability of vancomycin is not affected by the type of solvent,
since the formulations in the three different solvents did not show any significant decrease
or dissimilarity in stability over time. Additionally, no extra peaks of impurities were
detected in any of the formulations by the HPLC analysis, suggesting that vancomycin
does not undergo degradation in these solvents.
Further, we tested whether the storage temperature can affect the stability of van-
comycin for any of these ophthalmic formulations. The results of the present study demon-
strated no significant difference in vancomycin stability in any of the three formulations
based on their storage condition at room temperature or under refrigeration. Formulations
or drugs that require refrigeration impose many practical challenges, such as their trans-
portation from the pharmacy to a patient’s home and the storage while the patient is at
work or is traveling. Based on the results of the present study, it may be recommended
that patients can carry and store the compounded ophthalmic drops at room temperature,
avoiding excessive heat or direct sunlight as is generally recommended. Our results suggest
that there may not be a need for refrigeration over the concerns of losing the potency while
storing vancomycin ophthalmic drops at room temperature. Vancomycin is commonly
used in the antimicrobial therapy to treat hospital-acquired MRSA, and the common route
of administration is a slow intravenous infusion in 5% dextrose or normal saline. The sta-
bility of vancomycin at room temperature during a slow intravenous infusion is a concern.
Therefore, several previous studies have tested the stability of vancomycin for a shorter
duration, ranging from 1 h, 48 h, and 17 days when diluted in 5% dextrose or saline at
ambient temperature [30–35]. In agreement with the results of the present study, these
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studies also demonstrated that vancomycin is stable when stored at room temperature.
The results of the present study extend that stability for a longer duration of 28 days.
Further, the data from these previous studies also showed that plastic tubing or iv bags do
not cause vancomycin adsorption [30–35].
Although our study did not detect any differences in the stability of vancomycin
over 28 days of storage either at room temperature or refrigeration, we did observe a
difference in the pH and turbidity. It is worthwhile to note that vancomycin formulated
in PBS developed a visible turbidity, with a slight decrease in pH in storage both at room
temperature and under refrigeration. Vancomycin is available as a hydrochloride salt, and
its dissolution results in an acidic solution. As anticipated, the formulation in normal saline
offered no buffering, and this formulation had the most acidic pH. On the other hand, both
BSS and PBS offered some buffering capacity, and the pH of the vancomycin formulations
in these solvents were significantly less acidic. Acidic ophthalmic formulations may cause
a stinging sensation upon instillation, and our results suggest that vancomycin formulated
in normal saline may be less comfortable to the patient compared to the formulations in
PBS and BSS.
5. Conclusions
In conclusion, the results of the present study demonstrate that vancomycin oph-
thalmic drops prepared using PBS, BSS, and normal saline are stable up to the tested time
point of 28 days irrespective of their storage at room temperature or under refrigeration.
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